Compare BOX & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOX | TLX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 2014 | N/A |
| Metric | BOX | TLX |
|---|---|---|
| Price | $26.46 | $10.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $35.57 | $21.13 |
| AVG Volume (30 Days) | ★ 2.0M | 202.9K |
| Earning Date | 05-26-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $506,142,000.00 | N/A |
| Revenue This Year | $9.41 | N/A |
| Revenue Next Year | $8.15 | N/A |
| P/E Ratio | $311.63 | ★ $150.33 |
| Revenue Growth | ★ 26.98 | N/A |
| 52 Week Low | $21.34 | $6.28 |
| 52 Week High | $34.39 | $16.95 |
| Indicator | BOX | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 62.06 |
| Support Level | $25.74 | $9.46 |
| Resistance Level | $26.45 | $11.28 |
| Average True Range (ATR) | 0.81 | 0.28 |
| MACD | -0.08 | 0.17 |
| Stochastic Oscillator | 78.93 | 77.15 |
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.